Original articleAnti-TNFα Treatment for HLA-B27-Positive Ankylosing Spondylitis–Related Uveitis
Section snippets
Methods
This retrospective cohort study comprised 143 patients diagnosed with HLA-B27-positive AS. All participants were recruited from May 2006 to August 2015 at Seoul St. Mary's Hospital in South Korea, and a retrospective chart review was conducted. Inclusion criteria were a proven diagnosis of AS, HLA-B27-positive antigen test, and patients who were prescribed an anti-TNFα agent (infliximab, adalimumab, or etanercept) for at least 1 year. AS was diagnosed according to the Modified New York Criteria
Demographic and Clinical Characteristics
Table 1 shows the clinical characteristics of the 143 study participants. Their mean age was 41.0 ± 13.0 years, and 97 patients (67.8%) were male. Table 1 summarizes the demographic and clinical characteristics of uveitis in the 3 groups. Before anti-TNFα treatment, 94 patients (65.7%) (42 [63.6%] in Group 1, 33 [73.3%] in Group 2, and 19 [59.4%] in Group 3) had a history of uveitis. In patients with history of uveitis, anterior uveitis was the most common (37 [88.1%] in Group 1, 32 [97.0%] in
Discussion
In agreement with a number of previously published reports,16, 17, 18, 20, 22, 29, 30, 31 this study showed that all 3 anti-TNFα agents induced improved activity of uveitis and successfully prevented uveitis relapse. However, we are unaware of previous reports regarding the efficacy of anti-TNFα agents in the HLA-B27-positive AS group. This is the report showing uveitis improvement efficacy of anti-TNFα agents in patients with HLA-B27-positive AS.
Infliximab and adalimumab are immunoglobulin
References (46)
- et al.
Anterior uveitis and hypopyon
Am J Ophthalmol
(1991) - et al.
Outcomes in anterior uveitis associated with the HLA-B27 haplotype
Ophthalmology
(1998) - et al.
Anti-tumor necrosis factor-alpha therapy in uveitis
Surv Ophthalmol
(2015) - et al.
Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection
Semin Arthritis Rheum
(2006) - et al.
Hearing and cochlear function of patients with ankylosing spondylitis
Clin Rheumatol
(2012) - et al.
The spondyloarthritides
- et al.
Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors
Arthritis Rheum
(1998) - et al.
Global prevalence of ankylosing spondylitis
Rheumatology (Oxford)
(2014) - et al.
The outcome of ankylosing spondylitis: a study of 100 patients
Br J Rheumatol
(1997) - et al.
HLA-B27 positive patients differ from HLA-B27 negative patients in clinical presentation and imaging: results from the DESIR cohort of patients with recent onset axial spondyloarthritis
Ann Rheum Dis
(2011)
Acute anterior uveitis (AAU) and HLA-B27
Br J Rheumatol
Clinical features and outcomes of HLA-b27-positive and HLA-B27-negative acute anterior uveitis in a Turkish patient population
Ocul Immunol Inflamm
HLA-B27 typing in the categorisation of uveitis in a HLA-B27 rich population
Br J Ophthalmol
Characterization and outcome of uveitis in 350 patients with spondyloarthropathies
Rheumatol Int
Posterior segment inflammation in HLA-B27+ acute anterior uveitis: clinical characteristics
Ocul Immunol Inflamm
The pathophysiology of tumor necrosis factors
Annu Rev Immunol
TNF-R1 signaling: a beautiful pathway
Science
Anti-TNF therapy for juvenile idiopathic arthritis-related uveitis
Drug Des Devel Ther
Biologic treatments for systemic rheumatic diseases
Oral Dis
Anti-TNF-alpha therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients
Rheumatology (Oxford)
Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis
Ophthalmic Res
Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study
Ann Rheum Dis
Long-term efficacy of systemic infliximab in recalcitrant retinal vasculitis
Retina
Cited by (28)
Uveitis treated with biotherapy and/or DMARD: Analysis from the French Pharmacovigilance Study Base
2018, Journal Francais d'OphtalmologieThe eye and inflammatory rheumatic diseases: The eye and rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis
2016, Best Practice and Research: Clinical RheumatologyCitation Excerpt :There is debate on whether etanercept itself can cause uveitis [57,62–65]. The use of powerful systemic immune modulators to prevent recurrences of AU that are normally not sight threatening and can be unpredictable should be balanced against the potential side effects [66] and cost–benefit analysis of treatment. Gao et al. assessed uveitis flare rates in patients with AS treated with anti-TNF agents and examined the economic burden of uveitis.
Clinical characterization of patients with HLA-B27-associated uveitis and evaluation of the impact of systemic treatment on the recurrence rate: a cross-sectional study
2023, Journal of Ophthalmic Inflammation and Infection